EXCHANGE AGREEMENTExchange Agreement • February 2nd, 2024 • Origin Life Sciences, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Exchange Agreement (this “Agreement”), dated as of February [ ], 2024, is made by and between Origin Life Sciences, Inc., a Delaware corporation (the “Company”), and Victor Micati, as the holder of the Debt (as defined below) (the “Holder” and, together with the Company, the “Parties” and each individually a “Party”).
EXCHANGE AGREEMENTExchange Agreement • February 2nd, 2024 • Origin Life Sciences, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Exchange Agreement (this “Agreement”), dated as of January 31, 2024, is made by and between Origin Life Sciences, Inc., a Delaware corporation (the “Company”), and LF Equity Income Fund, a sub-fund of LF Investment Fund, acting by its authorized corporate director, Link Fund Solutions Limited, as the holder of the Securities (as defined below) (the “Holder” and, together with the Company, the “Parties” and each individually a “Party”).
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • February 2nd, 2024 • Origin Life Sciences, Inc. • Electromedical & electrotherapeutic apparatus • New Jersey
This Amendment No. 1 (this “Amendment”), effective as of January 31, 2024, to the Employment Agreement, dated November 15, 2022 (the “Employment Agreement”), by and between Origin Life Sciences, Inc. f/k/a Origin, Inc. (the “Company”) and Dr. Terry Treadwell (“Executive”). Capitalized terms used herein without definition shall have the meanings assigned in the Employment Agreement.
